Diabetic retinopathy. Pathophysiology and therapy of hypoxia-induced inflammation;Diabetische retinopathie. Pathophysiologie und therapie einer hypoxieinduzierten entzündung

Ophthalmologe

Volumn 100, Issue 5, 2003, Pages 363-370

  Joussen, Antonia M ^a   Fauser, S ^a   Krohne, T U ^a   Lemmen, K D ^b   Lang, G E ^c   Kirchhof, B ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b St Martinus Krankenhaus Dusseldorf   (Germany)

^c NONE

Author keywords

Diabetic retinopathy; Growth factors; Hypoerglycemia; Leukocytes; Pericytes; Retinal endothelial cells

Indexed keywords

CYTOKINE; GROWTH FACTOR; VASCULOTROPIN;

ARTICLE; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; HUMAN; HYPERGLYCEMIA; HYPOXIA; INFLAMMATION; PATHOPHYSIOLOGY; PERICYTE; RETINA CAPILLARY; RETINA NEOVASCULARIZATION;

EID: 0037600389     PISSN: 0941293X     EISSN: 14330423     Source Type: Journal    
DOI: 10.1007/s00347-003-0800-8     Document Type: Article

References (66)

1. The Lancet (1997) A curious stopping rule from Hoechst Marion Roussel. Lancet 350:155
2. Adamis AP, Miller JW, Bernal MT et al. (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450
3. Adamis AP, Shima DT, Tolentino MJ et al. (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66-71
4. Agardh CD, Eckert B, Agardh E (1992) Irreversible progression of severe retinopathy in young type I insulin dependent diabetes mellitus patients after improved metabolic control. J Diabetes Complications 6:96-100
5. Aiello LP, Pierce EA, Foley ED et al. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92:10457-10461
6. Bless NM, Huber-Lang M, Guo RF et al. (2000) Role of CC chemokines (macrophage inflammatory protein-1 beta, monocyte chemoattractant protein-1, RANTES) in acute lung injury in rats. J Immunol 164:2650-2659
7. Boehm BO, Feldmann B, Lang GK, Lang GE (1999) Treatment of diabetic retinopathy with long-acting somatostatin analogues. In: Lamberts SWJ (ed) Octreotide: the next Decade. Bio Scientifica Ltd, Bristol, pp 241-257
8. Boehm BO, Lang GK, Jehle PM et al. (2001) Octreotide reduceds vetreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 33:300-306
9. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
10. Cardier JE, Schulte T, Kammer H et al. (1999) Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells. Faseb J 13:1950-1960
11. Caro J (2001) Hypoxia regulation of gene transcription. High Alt Med Biol 2:145-154
12. Chaturvedi N, Sjolie AK, Stephenson JM et al. (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351:28-31
13. Clancy R, Varenika B, Huang W et al. (2000) Nitric oxide synthase/COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production. J Immunol 165:1582-1587
14. Cooper ME (2000) Angiotensin II antagonist versus ACE inhibition in the therapy of retinal disease. J Renin Angiotensin Aldosterone System 1:1-67
15. Damert A, Ikeda E, Risau W (1997) Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J 327 (Pt 2):419-423
16. Danis RP, Bingaman DP (1997) Insulin-like growth factor-1 retinal microangiopathy in the pig eye. Ophthalmology 104:1661-1669
17. Diabetes Control and Complications Trial Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
18. Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group (1995) Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 102:647-661
19. Early Treatment Diabetic Retinopathy Study Research Group (1991) Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology 98:757-765
20. Feldmann B, Jehle PM, Mohan S et al. (2000) Diabetic retinopathy is associated with decreased serum levels of free IGF-1 and changes of IGF-binding proteins. Growth Hormone IGF Research 10:53-60
21. Frank RN, Amin R, Kennedy A, Hohman TC (1997) An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch Ophthalmol 115:1036-1047
22. Freedman BI, Wuerth JP, Cartwright K et al. (1999) Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20:493-510
23. Grant MB, Mames RN, Fitzgerald C et al. (2000) The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23:504-509
24. Growth hormone Antagonist for Proliferative Diabetic Retinopathy Study Group (2001) The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 108:2266-2272
25. Henricsson M, Janzon L, Groop L (1995) Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with NIDDM. Diabetes Care 18:1571-1576
26. Henricsson M, Nilsson A, Janzon L, Groop L (1997) The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 14:123-131
27. Jeffcoate W (2000) Can growth hormone therapy cause diabetes? Lancet 355:589-590
28. Joussen AM, Murata T, Tsujikawa A et al. (2001) Leukocytes mediate cell death and injury in diabetic retinopathy. Am J Pathol 158:147-152
29. Joussen AM, Poulaki V, Tsujikawa A et al. (2002) Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 160:1683-1693
30. Joussen AM, Poulaki V, Qin W et al. (2002) Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 160:501-509
31. Joussen AM, Poulaki V, Mitsiades N et al. (2002) Potential use of non-steroidal anti-inflammatory drugs for prevention of diabetic vascular changes: Aspirin prevents diabetic leakage and leukocyte adhesion through inhibition of TNF-a. FASEB J 16:438-440
32. Joussen AM, Poulaki V, Mitsiades N et al. (in press) Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. Faseb J
33. Kern TS, Engerman RL (2001) Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 50:1636-1642
34. Khosla PK, Seth V, Tiwari HK, Saraya AK (1982) Effect of aspirin on platelet aggregation in diabetes mellitus. Diabetologia 23:104-107
35. Koya D, Jirousek MR, Lin YW et al. (1997) Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100:115-126
36. Kuroki M, Voest EE, Amano S et al. (1996) Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98:1667-1675
37. Lang GE, Kampmeier J (2002) Die Bedeutung der Proteinkinase C in der Pathophysiologie der diabetischen Retinopathie. Klein Monatsbl Augenheilkd 219:769-776
38. Loetscher P, Seitz M, Clark-Lewis I et al. (1994) Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. Faseb J 8:1055-1060
39. Lutty GA, Cao J, McLeod DS (1997) Relationship of polymorphonuclear leukocytes to capillary dropout in the human diabetic choroid. Am J Pathol 151:707-714
40. Malecaze F, Clamens S, Simorre-Pinatel V et al. (1994) Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112:1476-1482
41. McCormack K (1998) Roles of COX-1 and COX-2. J Rheumatol 25:2279-2281
42. McLeod DS, Lefer DJ, Merges C, Lutty GA (1995) Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 147:642-653
43. Merimee TJ (1978) A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. N Engl J Med 298:1217-1222
44. Meyer-Schwickerath R, Pfeiffer A, Blum WF et al. (1993) Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest 92:2620-2625
45. Miyamoto K, Ogura Y (1999) Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol 14:233-239
46. Moskalets E, Galstyan G, Starostina E et al. (1994) Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. J Diabetes Complications 8:45-50
47. Moynagh PN, Williams DC, O'Neill LA (1994) Activation of NF-kappa B and induction of vascular cell adhesion molecule-1 and intracellular adhesion molecule-1 expression in human glial cells by IL-1. Modulation by antioxidants. J Immunol 153:2681-2690
48. Mukhopadhyay D, Tsiokas L, Zhou XM et al. (1995) Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375:577-581
49. Murata T, Nakagawa K, Khalil A et al. (1996) The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 74:819-825
50. Pairet M, Engelhardt G (1996) Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 10:1-17
51. Pillinger MH, Capodici C, Rosenthal P et al. (1998) Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrindependent neutrophil adhesion. Proc Natl Acad Sci USA 95:14540-14545
52. Poulaki V, Qin W, Joussen AM et al. (2002) Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest 109:805-815
53. Powell CJ Jr, Finkelstein RA (1964) Polymyxin agar as an adjunct in the isolation of El Tor vibrios. J Bacteriol 87:1249-1250
54. Punglia RS, Lu M, Hsu J et al. (1997) Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46:1619-1626
55. Qaum T, Xu Q, Joussen AM et al. (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408-2413
56. Schröder S, Palinski W, Schmid-Schönbein GW (1991) Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 139:81-100
57. Shweiki D, Neeman M, Itin A, Keshet E (1995) Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 92:768-772
58. Simpson HL, Umpleby AM, Russell-Jones DL (1998) Insulin-like growth factor-I and diabetes. A review. Growth Horm IGF Res 8:83-95
59. Schmidt-Schönbein H, Volger E (1976) Red-cell aggregation and red-cell defromability in diabetes. Diabetes 25:897-902
60. Smith LE, Kopchick JJ, Chen W et al. (1997) Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276:1706-1709
61. Weissmann G (1991) The actions of NSAIDs. Hosp Pract (Off Ed) 26:60-68, 71-62, 75-66
62. Wetsel WC, Khan WA, Merchenthaler I et al. (1992) Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol 117:121-133
63. Williams B, Schrier RW (1993) Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J Clin Invest 92:2889-2896
64. Williamson JR, Chang K, Frangos M et al. (1993) Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813
65. Xia P, Inoguchi T, Kern TS et al. (1994) Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hyper-galactosemia. Diabetes 43:1122-1129
66. Zelzer E, Levy Y, Kahana C et al. (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. Embo J 17:5085-5094